Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CV 301

Next Previous
Drug Profile

CV 301

Alternative Names: CEA-MUC-1-TRICOM Vaccine; CEA-MUC-1/TRICOM; CV-301; CVAC-301; Falimarev-inalimarev; Inalimarev-falimarev; PANVAC; PANVAC V/F; PANVAC-VF

Latest Information Update: 23 Oct 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Therion Biologics
  • Developer BN ImmunoTherapeutics; Bristol-Myers Squibb; National Cancer Institute (USA); Therion Biologics
  • Class Cancer vaccines; Membrane glycoproteins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Pancreatic cancer
  • Phase II Bladder cancer; Colorectal cancer; Non-small cell lung cancer; Prostate cancer
  • Discontinued Breast cancer; Ovarian cancer

Most Recent Events

  • 01 Aug 2023 Georgetown University terminates a phase I/II trial in Pancreatic cancer and Colorectal cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (SC), due to lack of enrollment (NCT03376659)
  • 10 Sep 2021 Efficacy data from a phase II trial in Bladder cancer presented at the 116th Annual Meeting of the American Urological Association (AUA-2021)
  • 19 Feb 2021 Phase II development in Prostate cancer (Combination therapy, Metastatic disease) is still ongoing in USA (SC) (NCT03315871)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top